Trial Profile

An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 23 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary) ; Capecitabine
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
Focus Registrational; Therapeutic Use
Acronyms SOLSTICE

19 Dec 2024 Planned End Date changed from 30 Jun 2024 to 31 Dec 2025.
31 Aug 2024 This trial has been completed in Czechia according to European Clinical Trials Database record.
25 Aug 2024 The study has been completed in Latvia, according to the European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com